Notícias

While new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constantly emerge to prolong the pandemic of COVID-19, robust...

Abstract

The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a...

BACKGROUND

The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster vaccine are not known.

Background

Updated immunization strategies are needed to address multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Here we report interim...

Não perca nesta quinta, dia 13, o seminário “Fortalecimento e sustentabilidade do setor farmoquímico nacional”, que ABIFINA e Fiocruz promovem...

José Luis Gordon, presidente da Embrapii, e Marcus Soalheiro, presidente do Conselho Administrativo da ABIFINA

Parceria foi anunciada durante encontro...

Em outubro, empresa promove sua já tradicional campanha com ações educativas para conscientização de colaboradores e público externo sobre a...

Odilon José da Costa Filho assume a Vice-presidência de Relações Institucionais do Laboratório Cristália. Odilon iniciou sua carreira no Cristália...

Coronavirus disease 2019 (COVID-19) is a highly infectious respiratory disease caused by a severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). SARS-CoV-2 infection...

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic....

ABSTRACT

Three directly acting antivirals (DAAs) demonstrated substantial reduction in COVID-19 hospitalizations and deaths in clinical trials. However, these agents...